RxDoctor Payments Data

Monty Glorioso, MD

Internal Medicine · Metairie, LANPI 1962467191

Payments from drug & device makers

$6,811in general payments, 2019–2025

Across 341 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$749
  • Pfizer$748
  • GSK$681
  • Novo Nordisk$595
  • Lilly USA, LLC$446
  • Johnson & Johnson$387
  • plus $3K from 31 others

What the payments were for

  • Food & beverage$6,811100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,811 in reported general payments places this provider in the 90th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$80,367
Medicare patients
341
Services billed
1,009

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban234$252,996
OzempicSemaglutide121$139,404
JardianceEmpagliflozin78$96,088
FarxigaDapagliflozin Propanediol57$57,151
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$40,966
VascepaIcosapent Ethyl59$40,358
JanuviaSitagliptin Phosphate31$37,259
XareltoRivaroxaban26$35,228
MyrbetriqMirabegron31$30,911
MounjaroTirzepatide24$26,742
TradjentaLinagliptin16$24,523
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$19,408
JanumetSitagliptin Phos/Metformin Hcl17$19,319
TrulicityDulaglutide15$14,741
GemtesaVibegron18$13,222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$748$257,660247 claims
Novo NordiskOzempic$595$139,404121 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$186$126,510106 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$749$72,16089 claims
GSKTrelegy Ellipta, Anoro Ellipta$681$60,37589 claims
MerckJanuvia, Janumet$57$56,57848 claims
Lilly USA, LLCMounjaro, Trulicity$446$41,48439 claims
Johnson & JohnsonXarelto$387$35,22826 claims
Astellas Pharma US IncMyrbetriq$300$30,91131 claims
Sumitomo Pharma America, Inc.Gemtesa$243$13,22218 claims
AbbVieSynthroid$380$5,59051 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →